Drug Detail

Drug Name Cyclophosphamide
Trade Name Cytoxan
Synonyms CPM
Drug Descriptions

Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).

DrugClasses Chemotherapy - Alkylating 14

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Cyclophosphamide + Doxorubicin + Pertuzumab + Tamoxifen + Trastuzumab
Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus
MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone
Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase
Cyclophosphamide + Sorafenib + Topotecan
NANT triple negative breast cancer vaccine combination
Epirubicin + Cyclophosphamide
Cisplatin + Cyclophosphamide + Etoposide + Vincristine sulfate liposome
Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide
Pembrolizumab + DPX-Survivac + Cyclophosphamide
Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab
Cyclophosphamide + Fludarabine
Cyclophosphamide + Doxorubicin + Eribulin
Bortezomib + Cyclophosphamide
Cyclophosphamide + GVAX pancreatic cancer vaccine + Nivolumab
REGN2810 + GM-CSF + Cyclophosphamide
Venetoclax + DA-EPOCH-R
Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab
Cyclophosphamide + PD 0360324
Cisplatin + Cyclophosphamide + Etoposide
Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide
CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab
CHOP + Rituximab
Cyclophosphamide + NeoVax Limited information is currently available on NeoVax, a putative peptide personalized tumor vaccine (Aug 2018).
MEDI4736 + R2-CHOP
Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others
Cyclophosphamide + Pegfilgrastim + VTX-2337
Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM
HS-110 + Cyclophosphamide
Rituximab + Fludarabine + EPOCH
Busulfan + Fludarabine phosphate + Cyclophosphamide
Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110
CHOP + Obinutuzumab + RO7082859
Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab
Cyclophosphamide + IRX-2 + Nivolumab
Bortezomib + Cyclophosphamide + lenalidomide
Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab
Asparaginase + Cyclophosphamide + Etoposide
Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab
Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide
Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab
NANT non-small cell lung cancer vaccine
CHOP + Rituximab + TAK-659
Vincristine + Dactinomycin + Cyclophosphamide
Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM
Cyclophosphamide + MM-398 MM-398 (PEP02) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680).
Fludarabine + EPOCH
Cyclophosphamide + Indomethacin + IRX-2
Cyclophosphamide + Dexamethasone + Mesna
Cyclophosphamide + Dexamethasone + Venetoclax + Vincristine
Bevacizumab + Cyclophosphamide + Zoledronic acid
CHOP + Rituximab + RO7082859
Cyclophosphamide + GVAX pancreatic cancer vaccine
Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab
CHOP + Nivolumab + Rituximab
Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide
Ara-C + Cyclophosphamide + Inotuzumab ozogamicin + Methotrexate + Vincristine
Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide
Vandetanib + Cyclophosphamide + Methotrexate
Cyclophosphamide + Prednisone + Vincristine
EPOCH
Clofarabine + Etoposide + Cyclophosphamide
Cyclophosphamide + Fludarabine phosphate + Tisagenlecleucel
Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM
Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone
Cyclophosphamide + Pentostatin
Cyclophosphamide + Dexamethasone + Rituximab + Venetoclax + Vincristine
Cyclophosphamide + Prednisone + Rituximab + Vincristine
Cyclophosphamide + Indomethacin
inotuzumab ozogamicin + cyclophosphamide + prednisone + rituximab + vincristine
Cyclophosphamide + Fludarabine + IL-12 + LN-145 + Mesna
Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine
CRS-207 + Cyclophosphamide + GVAX pancreatic vaccine + Ipilimumab + Nivolumab
Aldesleukin + Cyclophosphamide + Naxitamab
Cyclophosphamide + ONCOS-102 + Pembrolizumab
Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine
Cyclophosphamide + Fludarabine + Mycophenolate mofetil
Aldesleukin + Cyclophosphamide + ID-LV305
Cyclophosphamide + Cytarabine
Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine
Bevacizumab + Cyclophosphamide + Sorafenib
Doxorubicin + Cyclophosphamide
Cyclophosphamide + Topotecan + Bevacizumab
Aldesleukin + Cyclophosphamide + Fludarabine phosphate + IMA101 T cells
Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine
Cyclophosphamide + Dasatinib + Temsirolimus
Cyclophosphamide + Doxorubicin + Elenagen
Autologous TAPA-pulsed dendritic cell vaccine + Cyclophosphamide
AC + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab
Bevacizumab + Docetaxel + Fluorouracil + Epirubicin + Cyclophosphamide
Docetaxel + Cyclophosphamide
EPOCH + Nivolumab
Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab
Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin
Cyclophosphamide
Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab
AC + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab
BC8-B10 + Cyclophosphamide + Fludarabine BC8-B10 is a radioimmunoconjugate that contains anti-CD45 monoclonal antibody BC8 with its lysine side groups conjugated with decoborate and labeled with Astatine (NCI Drug Dictionary). BC8-B10 prolongs survival of mice with disseminated murine leukemia in conjugation with bone marrow transplant (PMID: 23471305).
Methotrexate + Cisplatin + Cyclophosphamide + Vincristine
Cyclophosphamide + Doxorubicin + Prednisone
Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone
Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase
Aldoxorubicin + Cyclophosphamide + Veliparib
COPDAC-28 + Pembrolizumab
Allopurinol + Cyclophosphamide + Fludarabine
Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin
Docetaxel + Cyclophosphamide + Trastuzumab
Aldesleukin + Cyclophosphamide + Pembrolizumab
ALT-803 + Cyclophosphamide + Fludarabine phosphate
Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305
R-MACLO/IVAM
Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide
BTCT4465A + CHOP
Cyclophosphamide + Epirubicin + Pembrolizumab
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine
Cyclophosphamide + Fludarabine + Rituximab
Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab
Cyclophosphamide + Fludarabine phosphate + Nivolumab
Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus
Paclitaxel + Doxorubicin + Cyclophosphamide
Cyclophosphamide + Doxorubicin + Vincristine
Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab
NANT colorectal cancer vaccine combination
Cyclophosphamide + Etoposide + Topotecan
AC + Anastrozole + Paclitaxel + Pertuzumab + Trastuzumab
Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel Limited information is currently available on EG12014 (Jan, 2019).
Aldesleukin + Cyclophosphamide + Utomilumab
Cyclophosphamide + Doxorubicin + Pembrolizumab
Cyclophosphamide + Cisplatin + Vincristine
Cyclophosphamide + Paclitaxel
BTCT4465A + Cyclophosphamide + Doxorubicin + Polatuzumab Vedotin + Prednisone BTCT4465A is a bispecific antibody targeting CD20 and CD3, which results in killing of CD20-positive tumor cells (PMID: 25972002)
Cyclophosphamide + Fludarabine + Obinutuzumab
AC + exemestane + Paclitaxel + Pertuzumab + Trastuzumab
Fludarabine + Thiotepa + Cyclophosphamide
Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, urothelial carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
Erlotinib + Cyclophosphamide + Topotecan
NANT pancreatic cancer vaccine combination
Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib
Celecoxib + Cyclophosphamide + Etoposide + Sirolimus
Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin
Cyclophosphamide + Etoposide + Everolimus + Nelarabine
Cyclophosphamide + Fludarabine + Ofatumumab
Aldesleukin + Cyclophosphamide
Cyclophosphamide + Epirubicin + Paclitaxel + Trastuzumab
Obinutuzumab + CHOP
Cyclophosphamide + Paclitaxel + Trastuzumab
Cyclophosphamide + Methotrexate + Vincristine
Cyclophosphamide + Topotecan
Cyclophosphamide + Doxorubicin + Rituximab + Polatuzumab Vedotin + Prednisone
NANT hepatocellular carcinoma vaccine combination
Bevacizumab + Cyclophosphamide + Pembrolizumab
Cyclophosphamide + Fludarabine + Melphalan + Sirolimus
Cemiplimab + Cyclophosphamide
Busulfan + Cyclophosphamide + Etoposide
Crizotinib + Cyclophosphamide + Topotecan
Fluorouracil + Epirubicin + Cyclophosphamide
Cyclophosphamide + Nivolumab Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide
Cyclophosphamide + Durvalumab + Tremelimumab
Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab
Lorlatinib + Cyclophosphamide + Topotecan
Cyclophosphamide + Everolimus
Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel
Cisplatin + Doxorubicin + Cyclophosphamide
R-da-EPOCH
Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine phosphate + LY3039478
Cyclophosphamide + DPX-Survivac + INCB024360
Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK
Doxorubicin + Flourouracil + Cyclophosphamide
Cyclophosphamide + DPX-Survivac
Aldesleukin + Cyclophosphamide + Ipilimumab
Cyclophosphamide + Cetuximab
Cyclophosphamide + Epirubicin + Paclitaxel
Cyclophosphamide + DPX-E7
Nivolumab + REPOCH
Atezolizumab + Cyclophosphamide + Doxorubicin
R-EPOCH
Aldesleukin + Cyclophosphamide + Fludarabine
Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine
Anti-BCMA CAR T Cells + Cyclophosphamide + Fludarabine phosphate Anti-BCMA CAR T Cells are T-cells that express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), which may induce an enhanced anti-tumor immune response against BCMA-expressing tumor cells (PMID: 23344265).
Cyclophosphamide + Doxorubicin + Etoposide + Vincristine
Busulfan + Cyclophosphamide
R-CHP
SGT-53 + Cyclophosphamide + Topotecan
Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel
Sirolimus + Cyclophosphamide
KTE-C19 + Fludarabine phosphate + Cyclophosphamide
Cyclophosphamide + JCAR014 + MEDI4736
Cyclophosphamide + LCL161
Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine Anti-KRAS G12D murine T-cell receptor (mTCR) cells are peripheral blood lymphocytes that have been transduced with a murine T-cell receptor that recognizes KRAS G12D, which may result in decreased growth of tumors harboring KRAS G12D (PMID: 26701267).
Docetaxel + Doxorubicin + Cyclophosphamide
Cyclophosphamide + Pembrolizumab
Sirolimus + Cyclophosphamide + Topotecan
Carboplatin + Cyclophosphamide + Vincristine sulfate liposome
Cyclophosphamide + Etoposide
Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab
CC-122 + RCHOP
Cyclophosphamide + Pegaspargase + Vincristine
Cyclophosphamide + Nifurtimox + Topotecan
Cyclophosphamide + Dexamethasone + Lenalidomide
Bortezomib + Cyclophosphamide + G-CSF
Capecitabine + Cyclophosphamide + nab-paclitaxel
Cyclophosphamide + poly ICLC + Sargramostim
Veliparib + Cyclophosphamide
HPVSTs + Cyclophosphamide + Fludarabine phosphate + Nivolumab
INCB024360 + Pembrolizumab + Cyclophosphamide